Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9732571 | 0.88 | TBXAS1 (1.00) | TBXAS1TBXA2R | |
| Hydrochloric Acid SCHEMBL9732234 | 0.88 | TBXAS1 (1.00) | TBXAS1 | |
| Hydrochloric Acid SCHEMBL9733520 | 0.87 | TBXAS1 (1.00) | TBXAS1 | |
| Hydrochloric Acid SCHEMBL9732876 | 0.87 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL7766568 | 0.85 | TBXAS1 (0.80) | TBXAS1 | |
| SCHEMBL9222782 | 0.83 | TBXAS1 (0.70) | TBXAS1TBXA2R | |
| SCHEMBL3515640 | 0.83 | TBXAS1 (0.73) | TBXAS1 | |
| SCHEMBL9733697 | 0.81 | TBXAS1 (0.82) | TBXAS1TBXA2R | |
| SCHEMBL9732595 | 0.81 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL9732317 | 0.78 | TBXAS1 (0.94) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834820-B2 | Methods for the treatment and diagnosis of bone mineral density related diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-12-05 | — | — | US | disclosed |
| EP-2227560-B1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | INSERM - INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2017-10-18 | — | — | EP | disclosed |
| US-20150104437-A1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | Universite De Paris (FR) | 2015-04-16 | — | — | US | disclosed |
| US-20100284991-A1 | Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2010-11-11 | — | — | US | disclosed |
| EP-1242068-A4 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | NITROMED INC (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20030050305-A1 | Thromboxane inhibitors, compositions and methods of use | NITROMED, INC. | 2003-03-13 | — | — | US | disclosed |
| EP-1242068-A1 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | Nitromed, Inc. (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001089519-A1 | THROMBOXANE INHIBITORS, COMPOSITIONS AND METHODS OF USE RELATED APPLICATIONS | NITROMED, INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001032167-A1 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | NITROMED, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100284991-A1 | Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases | TBXAS1, TBXA2R, HPGDS | TBXAS1 1/4885TBXA2R 2/4885 |
| US-20150104437-A1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | TBXAS1, TBXA2R, HPGDS | TBXAS1 1/4885TBXA2R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.